MX2019012667A - Metodos de interrupcion de gen dirigido y composiciones inmunogenicas. - Google Patents

Metodos de interrupcion de gen dirigido y composiciones inmunogenicas.

Info

Publication number
MX2019012667A
MX2019012667A MX2019012667A MX2019012667A MX2019012667A MX 2019012667 A MX2019012667 A MX 2019012667A MX 2019012667 A MX2019012667 A MX 2019012667A MX 2019012667 A MX2019012667 A MX 2019012667A MX 2019012667 A MX2019012667 A MX 2019012667A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
genes
pathogens
targeted gene
gene disruption
Prior art date
Application number
MX2019012667A
Other languages
English (en)
Inventor
Wang Ying
R Ganta Roman
Original Assignee
Univ Kansas State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas State filed Critical Univ Kansas State
Publication of MX2019012667A publication Critical patent/MX2019012667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la interrupción dirigida de un gen específico y su restauración subsecuente en bacterias intracelulares obligadas sigue siendo extremadamente desafiante debido a su requerimiento absoluto para residencia dentro de una célula hospedera para replicarse. Aquí, las mutaciones de intercambio alélico dirigido se crearon para inactivar dos genes y después para restaurar uno de los dos genes de un patógeno rickettsial, Ehrlichia chaffeensis. Estos métodos también fueron exitosamente utilizados en Ehrlichia canis y Anaplasma phagocyophilum. Los patógenos mutados resultantes son útiles en las composiciones inmunogénicas para reducir la incidencia de, o severidad de la infección con patógenos rickettsiales.
MX2019012667A 2017-04-28 2018-04-30 Metodos de interrupcion de gen dirigido y composiciones inmunogenicas. MX2019012667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491896P 2017-04-28 2017-04-28
PCT/US2018/030302 WO2018201153A1 (en) 2017-04-28 2018-04-30 Targeted gene disruption methods and immunogenic compositions

Publications (1)

Publication Number Publication Date
MX2019012667A true MX2019012667A (es) 2020-01-21

Family

ID=63918799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012667A MX2019012667A (es) 2017-04-28 2018-04-30 Metodos de interrupcion de gen dirigido y composiciones inmunogenicas.

Country Status (10)

Country Link
US (1) US11541108B2 (es)
EP (1) EP3615049A4 (es)
JP (1) JP2020517722A (es)
KR (1) KR20200003039A (es)
CN (1) CN110913877A (es)
AU (1) AU2018256922A1 (es)
BR (1) BR112019022325A2 (es)
CA (1) CA3060320A1 (es)
MX (1) MX2019012667A (es)
WO (1) WO2018201153A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112175955B (zh) * 2020-10-29 2022-05-24 西南大学 一种在植物花粉中特异表达的强启动子cp09及其应用
AU2023224276A1 (en) * 2022-02-24 2024-08-22 Kansas State University Research Foundation Anaplasma vaccines and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653128B2 (en) * 1996-10-17 2003-11-25 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US7335754B2 (en) * 1999-07-21 2008-02-26 Cornell Research Foundation, Inc. Ehrlichia canis genes and vaccines
NZ532634A (en) * 2001-11-01 2006-09-29 Res Dev Foundation DNA encoding disulfide bond formation (Dsb) proteins from bacterial species of the genus Ehrlichia, such as Ehrlichia chaffeensis and Ehrlichia canis disulfide bond formation proteins.
WO2011041886A1 (en) * 2009-10-07 2011-04-14 University Of Victoria Innovation And Development Corporation Vaccines comprising heat-sensitive transgenes
AU2013341242B2 (en) * 2012-11-06 2018-06-28 Aduro Biotech, Inc. Facultatively attenuated bacterial species and methods of preparation and use thereof
WO2014113541A1 (en) * 2013-01-16 2014-07-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
US20180021421A1 (en) * 2015-01-19 2018-01-25 Kansas State University Research Foundation Attenuated vaccines to protect against tick-borne ehrlichia species infections

Also Published As

Publication number Publication date
AU2018256922A1 (en) 2019-11-28
BR112019022325A2 (pt) 2020-05-26
EP3615049A1 (en) 2020-03-04
KR20200003039A (ko) 2020-01-08
WO2018201153A1 (en) 2018-11-01
JP2020517722A (ja) 2020-06-18
US11541108B2 (en) 2023-01-03
EP3615049A4 (en) 2020-12-30
CN110913877A (zh) 2020-03-24
US20200188498A1 (en) 2020-06-18
CA3060320A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
FR22C1028I1 (fr) Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
CL2017003191A1 (es) Composiciones que comprenden cepas bacterianas
MX2018002346A (es) Composiciones y metodos para controlar enfermedades de plantas.
CL2017003193A1 (es) Composiciones que comprenden cepas bacterianas
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
MX2016009898A (es) Tratamientos para acne resistente.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
AR091582A1 (es) Vacunas atenuadas contra streptococcus suis y metodos de elaboracion y uso de las mismas
MX2019012667A (es) Metodos de interrupcion de gen dirigido y composiciones inmunogenicas.
EP3620178A3 (en) Antisense antibacterial compounds and methods
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
EP4241851A3 (en) Immunogenic compositions
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
MX365411B (es) Métodos para reducir el mal olor y las bacterias.
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
AU2016248452A8 (en) Bordetella pertussis immunogenic vaccine compositions
EA202190876A1 (ru) Композиции, содержащие бактериальные штаммы
EP4226937A3 (en) Non-neuroinvasive viruses and uses thereof
AR112644A1 (es) Cepas de agrobacterium tumefaciens
DK3571217T3 (da) Fremgangsmåder og sammensætninger til opnåelse af naturlig kompetence i bacillus-værtsceller
WO2016191695A3 (en) Treatments for obligately intracellular infections
GB2515222A (en) Use of flagellin as a vaccine